An optimal two-stage phase II design utilizing complete and partial response information separately
- 1 August 2002
- journal article
- Published by Elsevier in Controlled Clinical Trials
- Vol. 23 (4) , 367-379
- https://doi.org/10.1016/s0197-2456(02)00217-9
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Application of a New Multinomial Phase II Stopping Rule Using Response and Early ProgressionJournal of Clinical Oncology, 2001
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 1999
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSIONJournal of Biopharmaceutical Statistics, 1999
- Sample Size and Design Considerations for Phase II Clinical Trials with Correlated ObservationsControlled Clinical Trials, 1999
- Optimal flexible designs in phase II clinical trialsStatistics in Medicine, 1998
- Bayesian sequential monitoring designs for single‐arm clinical trials with multiple outcomesStatistics in Medicine, 1995
- Optimal Designs for a Grouped Sequential Binomial TrialBiometrics, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961